Last updated: 2026-09-09 04:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Zymeworks Inc. (ZYME) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $28.11, with a market capitalization of $2.09B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.69 to $31.34. This page covers its latest market performance, valuation, price trends and company information.
$2.09B | |
$28.93 | |
$59.03 | |
$4.11 | |
$29.19 | |
317.75K | |
617.85K | |
-- | |
$31.34 | |
$14.69 | |
-- | |
-- |
Zymeworks Inc. (ZYME) last closed at $29.19 as of 2026-09-08 23:31:00, unchanged from the previous close of $29.19.
During the latest regular trading session, ZYME traded between $4.11 and $59.03, with a volume of 317.75K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Zymeworks Inc. (ZYME) moved from $29.01 to $28.11, representing a decline of 3.11% ($0.90).
The stock traded between $27.71 and $31.34 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 634.65 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.6%
ZYME is currently trading at $28.11, placing it 80.6% of the way from its 52-week low of $14.69 to its 52-week high of $31.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 264 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zymeworks Inc. (ZYME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.